The DOI matches its Crossref record.
Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors
Abstract
We have recently demonstrated that human neutrophils (PMN) possess two different classes of adenosine receptors (A1 and A2) that, when occupied, promote chemotaxis and inhibit the generation of reactive oxygen species (e.g., O2- and H2O2), respectively. We have previously demonstrated that adenosine protects endothelial cells (EC) from injury by stimulated neutrophils (PMN) both by diminishing generation of H2O2 and inhibiting adherence of PMN to EC. We therefore determined whether occupancy of A1 or A2 adenosine receptors regulated adherence of PMN to EC. At concentrations similar to those required to inhibit release of O2- by ligation of A2 receptors, both adenosine (IC50 = 56 nM) and 5’N-ethylcarboxamidoadenosine (NECA, IC50 = 8 nM), the most potent A2 agonist, inhibited adherence to EC by stimulated PMN (FMLP, 0.1 microM). In direct contrast, the specific A1 agonists N6-phenylisopropyladenosine and N6-cyclopentyladenosine (CPA) promoted PMN adherence to EC at concentrations of 1-100 nM. To further investigate the mechanisms by which adenosine receptor agonists affected the adherence of stimulated PMN we examined the effect of NECA (A2) and CPA (A1) on the adherence of PMN to fibrinogen (a ligand for the beta 2 integrin CD11b/CD18) and to gelatin. In a dose-dependent manner (IC50 = 2 nM), NECA inhibited the adherence of FMLP-treated PMN to fibrinogen- but not gelatin-coated plates. In contrast, CPA (A1) promoted adherence of stimulated PMN to gelatin-(EC50 = 13 pM) but not fibrinogen-coated plates. Theophylline (10 microM), an adenosine receptor antagonist, reversed the inhibition by NECA (0.3 microM) of stimulated neutrophil adherence to fibrinogen. These observations not only confirm the presence of A1 and A2 receptors on PMN but also suggest two opposing roles for adenosine in inflammation. Occupancy of A1 receptors promotes neutrophil adherence to endothelium and chemotaxis (a proinflammatory role) whereas occupancy of A2 receptors inhibits adherence and generation of toxic oxygen metabolites (an antiinflammatory role).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Receptors for Purines and Pyrimidines
Burnstock, G., & Verkhratsky, A. (2012) · Purinergic Signalling and the Nervous System · doi:10.1007/978-3-642-28863-0_5 · Cited by 3,958
Receptors for Purines and Pyrimidines
Ralevic, V., & Burnstock, G. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01373-5 · Cited by 2,005
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases
Haskó, G., Linden, J., Cronstein, B., & Pacher, P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2638 · Cited by 1,217
Self-citationBours, M. J. L., Swennen, E. L. R., Di Virgilio, F., Cronstein, B. N., & Dagnelie, P. C. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.04.013 · Cited by 1,030
Self-citationAdhesion molecules and inflammatory injury
Albelda, S. M., Smith, C. W., & Ward, P. A. (1994) · The FASEB Journal · doi:10.1096/fasebj.8.8.8181668 · Cited by 1,015
The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion
Granger, D. N., & Kubes, P. (1994) · Journal of Leukocyte Biology · doi:10.1002/jlb.55.5.662 · Cited by 849
Targeting immunosuppressive adenosine in cancer
Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.86 · Cited by 840
Sayes, C. M., Wahi, R., Kurian, P. A., Liu, Y., West, J. L., Ausman, K. D., Warheit, D. B., & Colvin, V. L. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj197 · Cited by 838
Pharmacology of Adenosine Receptors: The State of the Art
Borea, P. A., Gessi, S., Merighi, S., Vincenzi, F., & Varani, K. (2018) · Physiological Reviews · doi:10.1152/physrev.00049.2017 · Cited by 783
Cronstein, B. N., Kimmel, S. C., Levin, R. I., Martiniuk, F., & Weissmann, G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.9991 · Cited by 725
Self-citationSitkovsky, M. V., Lukashev, D., Apasov, S., Kojima, H., Koshiba, M., Caldwell, C., Ohta, A., & Thiel, M. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104731 · Cited by 696
The role of neutrophils in myocardial ischemia–reperfusion injury
Jordan, J. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00187-x · Cited by 646
Adenosine, an endogenous anti-inflammatory agent
Cronstein, B. N. (1994) · Journal of Applied Physiology · doi:10.1152/jappl.1994.76.1.5 · Cited by 633
Self-citationMethotrexate—how does it really work?
Chan, E. S. L., & Cronstein, B. N. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.5 · Cited by 459
Self-citationMechanisms of action of methotrexate
Genestier, L., Paillot, R., Quemeneur, L., Izeradjene, K., & Revillard, J.-P. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00189-2 · Cited by 424
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Vigano, S., Alatzoglou, D., Irving, M., Ménétrier-Caux, C., Caux, C., Romero, P., & Coukos, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00925 · Cited by 420
Regulation of Inflammation by Adenosine
Haskó, G., & Cronstein, B. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00085 · Cited by 367
Self-citationResolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP
Bystrom, J., Evans, I., Newson, J., Stables, M., Toor, I., van Rooijen, N., Crawford, M., Colville-Nash, P., Farrow, S., & Gilroy, D. W. (2008) · Blood · doi:10.1182/blood-2007-12-129767 · Cited by 331
THE MECHANISM OF ACTION OF METHOTREXATE
Cronstein, B. N. (1997) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70358-6 · Cited by 312
Self-citationPurinergic signalling and immune cells
Burnstock, G., & Boeynaems, J.-M. (2014) · Purinergic Signalling · doi:10.1007/s11302-014-9427-2 · Cited by 309
Cell-surface enzymes in control of leukocyte trafficking
Salmi, M., & Jalkanen, S. (2005) · Nature Reviews Immunology · doi:10.1038/nri1705 · Cited by 281
Postconditioning: Reduction of reperfusion-induced injury
ZHAO, Z., & VINTENJOHANSEN, J. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.01.024 · Cited by 272
The ‘danger’ sensors that STOP the immune response: the A2 adenosine receptors?
Sitkovsky, M. V., & Ohta, A. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.04.004 · Cited by 265
Molecular therapeutics. Methotrexate and its mechanism of action
Cronstein, B. N. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780391203 · Cited by 265
Self-citationRegulation of Neutrophil Function by Adenosine
Barletta, K. E., Ley, K., & Mehrad, B. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.226845 · Cited by 260
The adhesion molecules of inflammation
Cronstein, B. N., & Weissmann, G. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360204 · Cited by 259
Self-citationAdenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases
Cronstein, B. N., & Sitkovsky, M. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.178 · Cited by 258
Self-citationAcute adenosinergic cardioprotection in ischemic-reperfused hearts.
Headrick, J. P., Hack, B., & Ashton, K. J. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00407.2003 · Cited by 171
New insights regarding the regulation of chemotaxis by nucleotides, adenosine, and their receptors
Corriden, R., & Insel, P. A. (2012) · Purinergic Signalling · doi:10.1007/s11302-012-9311-x · Cited by 78
Metadata
- Authors
- Cronstein, B. N., Levin, R. I., Philips, M., Hirschhorn, R., Abramson, S. B., & Weissmann, G.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1992-04-01
- Volume
- 148
- Issue
- 7
- Pages
- 2201-2206
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1898549991
- Cited by
- 365
- References
- 0
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.